333 related articles for article (PubMed ID: 36125064)
1. EGFR, the Lazarus target for precision oncology in glioblastoma.
Lin B; Ziebro J; Smithberger E; Skinner KR; Zhao E; Cloughesy TF; Binder ZA; O'Rourke DM; Nathanson DA; Furnari FB; Miller CR
Neuro Oncol; 2022 Dec; 24(12):2035-2062. PubMed ID: 36125064
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of EGFR Resistance in Glioblastoma.
Pan PC; Magge RS
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33187135
[TBL] [Abstract][Full Text] [Related]
3. Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges.
Reardon DA; Wen PY; Mellinghoff IK
Neuro Oncol; 2014 Oct; 16 Suppl 8(Suppl 8):viii7-13. PubMed ID: 25342602
[TBL] [Abstract][Full Text] [Related]
4. The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma.
Liu X; Chen X; Shi L; Shan Q; Cao Q; Yue C; Li H; Li S; Wang J; Gao S; Niu M; Yu R
J Exp Clin Cancer Res; 2019 May; 38(1):219. PubMed ID: 31122294
[TBL] [Abstract][Full Text] [Related]
5. Improving the efficacy of anti-EGFR drugs in GBM: Where we are going?
Ge M; Zhu Y; Wei M; Piao H; He M
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188996. PubMed ID: 37805108
[TBL] [Abstract][Full Text] [Related]
6. Identification of growth hormone receptor as a relevant target for precision medicine in low-EGFR expressing glioblastoma.
Verreault M; Segoviano Vilchis I; Rosenberg S; Lemaire N; Schmitt C; Guehennec J; Royer-Perron L; Thomas JL; Lam TT; Dingli F; Loew D; Ducray F; Paris S; Carpentier C; Marie Y; Laigle-Donadey F; Rousseau A; Pigat N; Boutillon F; Bielle F; Mokhtari K; Frank SJ; de Reyniès A; Hoang-Xuan K; Sanson M; Goffin V; Idbaih A
Clin Transl Med; 2022 Jul; 12(7):e939. PubMed ID: 35808822
[TBL] [Abstract][Full Text] [Related]
7. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
Taylor TE; Furnari FB; Cavenee WK
Curr Cancer Drug Targets; 2012 Mar; 12(3):197-209. PubMed ID: 22268382
[TBL] [Abstract][Full Text] [Related]
8. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
Acquaviva J; Jun HJ; Lessard J; Ruiz R; Zhu H; Donovan M; Woolfenden S; Boskovitz A; Raval A; Bronson RT; Pfannl R; Whittaker CA; Housman DE; Charest A
Cancer Res; 2011 Dec; 71(23):7198-206. PubMed ID: 21987724
[TBL] [Abstract][Full Text] [Related]
9. An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma.
Rodriguez SMB; Kamel A; Ciubotaru GV; Onose G; Sevastre AS; Sfredel V; Danoiu S; Dricu A; Tataranu LG
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446288
[TBL] [Abstract][Full Text] [Related]
10. Expression and pharmacological inhibition of TrkB and EGFR in glioblastoma.
Pinheiro KV; Thomaz A; Souza BK; Metcalfe VA; Freire NH; Brunetto AT; de Farias CB; Jaeger M; Bambini V; Smith CGS; Shaw L; Roesler R
Mol Biol Rep; 2020 Sep; 47(9):6817-6828. PubMed ID: 32862352
[TBL] [Abstract][Full Text] [Related]
11. A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma.
Kwatra MM
Curr Cancer Drug Targets; 2017; 17(3):290-296. PubMed ID: 28029074
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
13. EGF/EGFR upregulates and cooperates with Netrin-4 to protect glioblastoma cells from DNA damage-induced senescence.
Li L; Huang Y; Gao Y; Shi T; Xu Y; Li H; Hyytiäinen M; Keski-Oja J; Jiang Q; Hu Y; Du Z
BMC Cancer; 2018 Dec; 18(1):1215. PubMed ID: 30514230
[TBL] [Abstract][Full Text] [Related]
14. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.
Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS
Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588
[TBL] [Abstract][Full Text] [Related]
15. The tumor suppressor FOXO3a mediates the response to EGFR inhibition in glioblastoma cells.
Ramis G; Villalonga-Planells R; Serra-Sitjar M; Brell M; Fernández de Mattos S; Villalonga P
Cell Oncol (Dordr); 2019 Aug; 42(4):521-536. PubMed ID: 30980364
[TBL] [Abstract][Full Text] [Related]
16. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
[TBL] [Abstract][Full Text] [Related]
17. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.
Zheng Q; Han L; Dong Y; Tian J; Huang W; Liu Z; Jia X; Jiang T; Zhang J; Li X; Kang C; Ren H
Neuro Oncol; 2014 Sep; 16(9):1229-43. PubMed ID: 24861878
[TBL] [Abstract][Full Text] [Related]
18. Analysis of EGFR gene amplification, protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma.
Toth J; Egervari K; Klekner A; Bognar L; Szanto J; Nemes Z; Szollosi Z
Pathol Oncol Res; 2009 Jun; 15(2):225-9. PubMed ID: 18752056
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM.
McKinney A; Lindberg OR; Engler JR; Chen KY; Kumar A; Gong H; Lu KV; Simonds EF; Cloughesy TF; Liau LM; Prados M; Bollen AW; Berger MS; Shieh JTC; James CD; Nicolaides TP; Yong WH; Lai A; Hegi ME; Weiss WA; Phillips JJ
Mol Cancer Ther; 2019 Sep; 18(9):1565-1576. PubMed ID: 31270152
[TBL] [Abstract][Full Text] [Related]
20. EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.
Lo HW
Curr Mol Pharmacol; 2010 Jan; 3(1):37-52. PubMed ID: 20030624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
